NDAORALTABLET
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
E-Z-DISK (barium sulfate) by Bracco is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 2025.
Drug data last refreshed 11h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
E-Z-DISK is an oral barium sulfate tablet used as a radiographic contrast agent to enhance X-ray imaging of the gastrointestinal tract. It works by increasing radiodensity in target tissues, enabling clearer visualization during diagnostic imaging procedures. This NDA-approved product from Bracco launched in August 2025 as an oral formulation in a competitive contrast agent market.
Launch
Early-stage launch with moderate competitive pressure (30) indicates active go-to-market execution and potential for team growth during initial market penetration phase.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Career Relevance
E-Z-DISK represents a launch-phase diagnostic product with moderate competitive intensity, offering entry-level and mid-career opportunities primarily in commercial and marketing functions. Career advancement will depend on capturing market share against established competitors and Bracco's internal ISOVUE portfolio cannibalization risk.
Worked on E-Z-DISK at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.